CN113861167A - Preparation method of Voranolan fumarate - Google Patents

Preparation method of Voranolan fumarate Download PDF

Info

Publication number
CN113861167A
CN113861167A CN202111335839.7A CN202111335839A CN113861167A CN 113861167 A CN113861167 A CN 113861167A CN 202111335839 A CN202111335839 A CN 202111335839A CN 113861167 A CN113861167 A CN 113861167A
Authority
CN
China
Prior art keywords
formula
compound
azide
fumarate
compound shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111335839.7A
Other languages
Chinese (zh)
Inventor
徐晓东
王益平
韩延春
鲍晓伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Fuyuan Pharmaceutical Co ltd
Original Assignee
Beijing Fuyuan Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Fuyuan Pharmaceutical Co ltd filed Critical Beijing Fuyuan Pharmaceutical Co ltd
Priority to CN202111335839.7A priority Critical patent/CN113861167A/en
Publication of CN113861167A publication Critical patent/CN113861167A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • C07C51/412Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention provides a preparation method of Voranolan fumarate, which comprises the following steps: (1) carrying out an azide reaction on the compound of the formula I to obtain a compound of a formula II; (2) cyclizing the compound of the formula II and the compound of the formula III to obtain a compound of the formula IV; (3) carrying out condensation reaction on a compound shown in the formula IV and a compound shown in the formula VI to obtain a compound shown in the formula VII; (4) deprotecting the compound of formula VII with an acid to obtain Voronalane free base; (5) the Voranolan free alkali and fumaric acid form salt to obtain Voranolan fumarate. Compared with the prior art, the method for synthesizing the Voranolan fumarate has the advantages that the total yield of the Voranolan fumarate is improved to over 60 percent, and the yield is greatly improved. Furthermore, the compound of formula iv can be used as a new intermediate for the preparation of vorexant fumarate.

Description

Preparation method of Voranolan fumarate
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a preparation method of vorexant fumarate and an intermediate thereof.
Background
Vorexazol fumarate (Vonoprazan fumarate) is a novel gastric acid secretion inhibitor developed by martial arts, japan.
The chemical name of Voranolan fumarate is 5- (2-fluorophenyl) -N-methyl-1- (3-pyridylsulfonyl) -1H-pyrrole-3-methylamine fumarate, and the structural formula is shown as follows:
Figure BDA0003350475870000011
CN102421753A discloses a synthetic route of vorexant, which takes 5- (2-fluorophenyl) -2-chloro-1H-pyrrole-3-nitrile as raw material, and the total yield is about 39%. One of the intermediates in the reaction route disclosed in this patent is susceptible to side reactions in preparation and difficult to work up, resulting in a reduction in product yield.
Therefore, it is important to provide a preparation method of vorexant fumarate with high purity and high yield to solve the problem of low yield of vorexant.
Disclosure of Invention
The invention provides a preparation method of vorexant fumarate and an intermediate thereof. The total yield of the Voranolan fumarate prepared by the reaction route disclosed by the invention is over 60 percent.
The technical scheme adopted by the invention is as follows:
the invention discloses a method for preparing a compound shown as a formula VII, which comprises the following steps:
Figure BDA0003350475870000012
carrying out condensation reaction on a compound shown as a formula IV and a compound shown as a formula VI to obtain a compound shown as a formula VII
Figure BDA0003350475870000021
The condensation reaction catalyst is an organorhodium reagent and an acid catalyst. Preferably, the organorhodium reagent is dimeric rhodium acetate. Wherein the acid catalyst can be trifluoroacetic acid, trimethylsilyl trifluoromethanesulfonate (TMSOTf) and the like.
Deprotecting the compound represented by formula VII prepared by the above method with an acid to obtain Voranol free base; and salifying the Voranol free alkali and fumaric acid to obtain Voranol fumarate.
In another aspect of the invention, the invention also discloses a compound shown as a formula IV, which is used as an intermediate for preparing the vorexant fumarate:
Figure BDA0003350475870000022
in another aspect of the present invention, the present invention also discloses a method for preparing the compound represented by the formula IV, which comprises the following steps: cyclizing the compound shown as the formula II and the compound shown as the formula III to obtain the compound shown as the formula IV
Figure BDA0003350475870000023
The above cyclization reaction catalyst is a copper catalyst and a ligand. The copper catalyst is cuprous acetate, cupric sulfate or cuprous iodide. Preferably, the copper catalyst is copper acetate. The ligand is selected from one of aminophenol, phenylenediamine, benzenediol and aniline, wherein the aminophenol can be selected from 2-aminophenol, 3-aminophenol or 4-aminophenol; the phenylenediamine can be selected from o-phenylenediamine, m-phenylenediamine or p-phenylenediamine; the diphenol may be catechol, resorcinol or hydroquinone. Further preferably, the ligand is 2-aminophenol, 3-aminophenol, 4-aminophenol, catechol or hydroquinone.
In another aspect of the present invention, the present invention also discloses a method for preparing a compound represented by formula ii, comprising the steps of:
Figure BDA0003350475870000031
carrying out azide reaction on the compound shown as the formula I to obtain the compound shown as the formula II
Figure BDA0003350475870000032
In the above-mentioned azide reaction, the azide reagent is selected from one of sodium azide, potassium azide, lithium azide, magnesium azide, cesium azide and barium azide. Preferably, the azidation reagent is sodium azide. Further preferably, the azidation reaction system in step (1) further comprises a chlorination reagent and triphenylphosphine. Wherein the chlorinating agent is selected from one of thionyl chloride, oxalyl chloride and trichloroisocyanuric acid.
In another aspect of the invention, the invention discloses a preparation method of vorexant fumarate, which comprises the following steps:
(1) carrying out azide reaction on the compound shown as the formula I to obtain the compound shown as the formula II
Figure BDA0003350475870000033
(2) Cyclizing the compound shown as the formula II and the compound shown as the formula III to obtain the compound shown as the formula IV
Figure BDA0003350475870000041
(3) Carrying out condensation reaction on a compound shown as a formula IV and a compound shown as a formula VI to obtain a compound shown as a formula VII
Figure BDA0003350475870000042
(4) Deprotecting the compound shown in the formula VII by using acid to obtain Voronalane free base;
(5) the Voranolan free alkali and fumaric acid form salt to obtain Voranolan fumarate.
In the azide reaction in the step (1), the azide reagent is selected from one of sodium azide, potassium azide, lithium azide, magnesium azide, cesium azide and barium azide. Preferably, the azidation reagent is sodium azide. Further preferably, the azidation reaction system in step (1) further comprises a chlorination reagent and triphenylphosphine. Wherein the chlorinating agent is selected from one of thionyl chloride, oxalyl chloride and trichloroisocyanuric acid.
The cyclization reaction catalyst in the step (2) is a copper catalyst and a ligand. The copper catalyst is cuprous acetate, cupric sulfate or cuprous iodide. Preferably, the copper catalyst is copper acetate. The ligand is selected from one of aminophenol, phenylenediamine, benzenediol and aniline, wherein the aminophenol can be selected from 2-aminophenol, 3-aminophenol or 4-aminophenol; the phenylenediamine can be selected from o-phenylenediamine, m-phenylenediamine or p-phenylenediamine; the diphenol may be catechol, resorcinol or hydroquinone. Further preferably, the ligand is 2-aminophenol, 3-aminophenol, 4-aminophenol, catechol or hydroquinone.
The condensation reaction catalyst in the step (3) is an organic rhodium reagent and an acid catalyst. Preferably, the organorhodium reagent is dimeric rhodium acetate. Wherein the acid catalyst can be trifluoroacetic acid, trimethylsilyl trifluoromethanesulfonate (TMSOTf) and the like.
In another aspect of the invention, there is also disclosed a process for preparing a compound of formula VI, comprising the steps of,
Figure BDA0003350475870000051
carrying out condensation reaction on the compound shown as the formula V and a trimethyl silanization reagent to obtain the compound shown as the formula VI
Figure BDA0003350475870000052
The trimethylsilylating agent is selected from one of iodotrimethylsilane, bromotrimethylsilane, hexamethyldisilazane and trimethylsilyldiethylamine. In some embodiments, the iodotrimethylsilane is prepared from chlorotrimethylsilane (Me)3SiCl) and NaI.
Compared with the prior art, the method for synthesizing the Voranolan fumarate has the advantages that the total yield of the Voranolan fumarate is improved to over 60 percent, and the yield is greatly improved. Furthermore, the compound of formula iv can be used as a new intermediate for the preparation of vorexant fumarate.
Although the compounds obtained in each step can be used in the next reaction in the form of a reaction mixture or a crude product, they can also be easily separated and purified from the corresponding reaction mixture by known separation and purification means such as recrystallization, distillation, chromatography and the like.
The detailed reaction route of the preparation method of Voranolan fumarate disclosed by the invention is as follows:
Figure BDA0003350475870000061
in the step (1), the azide reaction system comprises an azide reagent. In some specific embodiments, the azide reaction system further comprises triphenylphosphine and a chlorinating agent, wherein the chlorinating agent may be selected from thionyl chloride, oxalyl chloride, trichloroisocyanuric acid, and the like. The reaction solvent is one or more selected from tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, DMF, ethyl acetate, xylene, trimethylbenzene, diethyl ether, isopropyl ether, methyl tert-butyl ether and methyl cyclopentyl ether.
In the step (2), the cycloaddition reaction of alkyne and azide is carried out at room temperature, and the reaction solvent is one or more selected from methanol, ethanol, isopropanol, ethylene glycol monomethyl ether, ethylene glycol monobutyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane and acetonitrile.
In the step (3), the molar ratio of the reaction of the formula VI to the reaction of the formula VI is 1:2-1: 4. 0.005-1mol of organic rhodium reagent is used per 1mol of compound VI; the acid catalyst is used in an amount of 0.025 to 5mol per 1mol of the compound VI. The reaction solvent is one or more selected from toluene, 2-methyltetrahydrofuran, dioxane, N-dimethylformamide, N-dimethylacetamide, 1, 2-dichloroethane, xylene, trimethylbenzene and methyl cyclopentyl ether.
In the step (4), the acid adopted for removing Boc from the compound VII is trifluoroacetic acid or hydrochloric acid to obtain Voranol free alkali, and then fumaric acid is added to obtain Voranol fumarate.
Detailed Description
Example 1
(1) Preparation of Compound II
Figure BDA0003350475870000071
Tetrahydrofuran is added into a reaction bottle, stirring is started, trichloroisocyanuric acid (13.9g, 0.06mol) is added, stirring is carried out until the solution is clear, triphenylphosphine (52.5g, 0.2mol) is added into the system at the temperature of 0-5 ℃ to form white suspension, compound I pyridine-3-sulfonic acid (15.9g, 0.1mol) is added into the reaction bottle, sodium azide (6.5g, 0.1mol) is added into the system, the temperature is raised to room temperature after the addition is finished, stirring is carried out at the room temperature until the reaction is finished, reduced pressure concentration is carried out until no fraction is produced, ethyl acetate and cold purified water are added into residues for washing, liquid separation is carried out, an organic phase is dried by anhydrous sodium sulfate, and compound II 17.3g is obtained after concentration, and the yield is 94%.
MS:m/z:185.0[M+1]
(2) Preparation of Compound IV
Figure BDA0003350475870000072
Acetonitrile is added into a reaction bottle at room temperature, stirring is started, a compound II (18.4g, 0.1mol), a compound III (18.6g, 0.11mol), 2-aminophenol (0.5g, 0.005mol) and copper acetate monohydrate (2g, 0.01mol) are added, stirring is carried out at room temperature until the reaction is finished, the reaction liquid is decompressed and concentrated to no fraction, and drying is carried out, so that 33.6g of a compound IV is obtained, and the yield is about 95%.
MS:m/z:354.1[M+1]
1H NMR(400MHz,CDCl3):1.42(s,9H),3.21(s,3H),4.22(d,2H),7.69(t,1H),8.32(s,1H), 8.43(d,1H),8.89-8.91(d,2H)
(3) Preparation of Compound VII
Figure BDA0003350475870000073
Adding 1.2-dichloroethane into a reaction bottle at room temperature, starting stirring, adding a compound IV (35.3g, 0.1mol), dimeric rhodium acetate (0.44g, 0.001mol) and a compound VI (63.1g,0.3mol), heating to 80 ℃ after the addition, stirring to react until the reaction is finished, cooling to room temperature, dissolving trimethylsilyl trifluoromethanesulfonate (TMSOTf) (1.1g, 0.005mol) in 1.2-dichloroethane, adding the system, stirring at room temperature, adding purified water and dichloromethane into the system for extraction, washing a water phase twice by using dichloro, combining organic phases, washing once by using water, and concentrating under reduced pressure to obtain 36.5g of a compound VII with the yield of about 82%.
MS:m/z:446.1[M+1]
(4) Preparation of Vonola fumarate
Figure BDA0003350475870000081
Adding a compound VII (44.6g, 0.1mol) into a reaction bottle at room temperature, adding trifluoroacetic acid (100ml), controlling the temperature to be 0-5 ℃ and stirring, adding a 20% sodium carbonate solution to adjust the pH value to be 9-10, collecting an organic phase, adding dichloromethane into a water phase to extract once, combining the organic phase, washing twice, drying the organic phase with anhydrous sodium sulfate, concentrating under reduced pressure to obtain Vonopalagen free alkali, adding methanol into the Vonopalagen free alkali to stir and dissolve, adding fumaric acid (11.6g, 0.1mol) into the reaction bottle at 25-30 ℃, heating to reflux, stirring, cooling, crystallizing and filtering, leaching a filter cake with methanol, drying by blowing at 40-50 ℃ to obtain 41.1g of Vonopalagen fumarate, wherein the yield is about 89%.
Example 2
(1) Preparation of Compound II
Figure BDA0003350475870000082
Adding methyl tert-butyl ether into a reaction bottle, starting stirring, adding thionyl chloride (7.14g, 0.06mol), stirring until the solution is clear, controlling the temperature to be 0-5 ℃, adding triphenylphosphine (52.5g, 0.2mol) into a system to form a white suspension, adding a compound I (15.9g, 0.1mol) into the reaction bottle, adding magnesium azide (10.8g, 0.1mol) into the system, heating to room temperature after the addition is finished, stirring at the room temperature until the reaction is finished, concentrating under reduced pressure until no fraction exists, adding ethyl acetate and cold purified water into residues, washing, separating, drying an organic phase by anhydrous sodium sulfate, and concentrating to obtain a compound II (16.9 g) with the yield of 92%.
MS:m/z:185.0[M+1]
(2) Preparation of Compound (IV)
Figure BDA0003350475870000091
Acetonitrile is added into a reaction bottle at room temperature, stirring is started, a compound II (18.4g, 0.1mol), a compound III (18.6g, 0.11mol), aniline (0.47g, 0.005mol) and cuprous iodide (1.9g, 0.01mol) are added, the reaction is stirred at room temperature until the reaction is finished, the reaction liquid is decompressed and concentrated to no fraction, and the reaction liquid is dried to obtain 32.5g of a compound IV, wherein the yield is about 92%.
MS:m/z:354.1[M+1]
1H NMR(400MHz,CDCl3):1.42(s,9H),3.21(s,3H),4.22(d,2H),7.69(t,1H),8.32(s,1H), 8.43(d,1H),8.89-8.91(d,2H)
(3) Preparation of Compound VII
Figure BDA0003350475870000092
Adding 1.2-dichloroethane into a reaction bottle at room temperature, starting stirring, adding a compound IV (35.3g, 0.1mol), dimeric rhodium acetate (0.44g, 0.001mol) and a compound VI (63.1g,0.3mol), heating to 80 ℃ after the addition, stirring to react until the reaction is finished, cooling to room temperature, dissolving trifluoroacetic acid (0.57g, 0.005mol) in 1.2-dichloroethane, adding the system, stirring at room temperature, adding purified water and dichloromethane into the system, extracting, washing the water phase twice with dichloro, combining the organic phases, washing once with water, concentrating under reduced pressure to obtain 37.0g of a compound VII with a yield of about 83%.
MS:m/z:446.1[M+1]
(4) Preparation of Vonola fumarate
Figure BDA0003350475870000101
Adding a compound VII (44.6g, 0.1mol) into a reaction bottle at room temperature, adding a proper amount of hydrochloric acid, stirring at the temperature of 0-5 ℃, adding a 20% sodium carbonate solution to adjust the pH value to 9-10, collecting an organic phase, adding dichloromethane into a water phase to extract once, combining the organic phases, washing twice, drying the organic phase with anhydrous sodium sulfate, concentrating under reduced pressure to obtain Vonopalagen free alkali, adding methanol into the Vonopalagen free alkali to stir and dissolve, adding fumaric acid (11.6g, 0.1mol) at the temperature of 25-30 ℃, heating to reflux, stirring, cooling, crystallizing, filtering, leaching a filter cake with methanol, and drying by air blowing at the temperature of 40-50 ℃ to obtain 41.5g of Vonopalagen fumarate, wherein the yield is about 90%.
Example 3
(1) Preparation of Compound II
Figure BDA0003350475870000102
Tetrahydrofuran is added into a reaction bottle, stirring is started, oxalyl chloride (7.6g, 0.06mol) is added, stirring is carried out until the mixture is dissolved, triphenylphosphine (52.5g, 0.2mol) is added into the system at the temperature of 0-5 ℃ to form white suspension, compound I (15.9g, 0.1mol) is added into the reaction bottle, potassium azide (8.1g, 0.1mol) is added into the system, the temperature is raised to room temperature after the addition, the mixture is stirred at the room temperature until the reaction is finished, the mixture is concentrated under reduced pressure until no fraction is formed, ethyl acetate and cold purified water are added into the residue to wash the mixture, the mixture is separated, the organic phase is dried by anhydrous sodium sulfate, and 17.5g of compound II is obtained after the concentration, and the yield is 95%.
MS:m/z:185.0[M+1]
(2) Preparation of Compound IV
Figure BDA0003350475870000103
Acetonitrile is added into a reaction bottle at room temperature, stirring is started, a compound II (18.4g, 0.1mol), a compound III (18.6g, 0.11mol), 4-aminophenol (0.5g, 0.005mol) and copper sulfate (2.5g, 0.01mol) are added, stirring is carried out at room temperature until the reaction is finished, the reaction liquid is decompressed and concentrated to no fraction, and drying is carried out, so that 33.2g of a compound IV is obtained, and the yield is about 94%.
MS:m/z:354.1[M+1]
1H NMR(400MHz,CDCl3):1.42(s,9H),3.21(s,3H),4.22(d,2H),7.69(t,1H),8.32(s,1H), 8.43(d,1H),8.89-8.91(d,2H)
(3) Preparation of Compound VII
Figure BDA0003350475870000111
Adding 1.2-dichloroethane into a reaction bottle at room temperature, starting stirring, adding a compound IV (35.3g, 0.1mol), dimeric rhodium acetate (0.44g, 0.001mol) and a compound VI (63.1g,0.3mol), heating to 80 ℃ after the addition, stirring to react until the reaction is finished, cooling to room temperature, dissolving trimethylsilyl trifluoromethanesulfonate (TMSOTf) (1.1g, 0.005mol) in 1.2-dichloroethane, adding the system, stirring at room temperature, adding purified water and dichloromethane into the system for extraction, washing a water phase twice by using dichloro, combining organic phases, washing once by using water, and concentrating under reduced pressure to obtain 37.4g of a compound VII with the yield of about 84%.
MS:m/z:446.1[M+1]
(4) Preparation of Vonola fumarate
Figure BDA0003350475870000112
Adding a compound VII (44.6g, 0.1mol) into a reaction bottle at room temperature, adding trifluoroacetic acid (100ml), controlling the temperature to be 0-5 ℃ and stirring, adding a 20% sodium carbonate solution to adjust the pH value to be 9-10, collecting an organic phase, adding dichloromethane into a water phase to extract once, combining the organic phase, washing twice, drying the organic phase with anhydrous sodium sulfate, concentrating under reduced pressure to obtain Vonopalagen free alkali, adding methanol into the Vonopalagen free alkali to stir and dissolve, adding fumaric acid (11.6g, 0.1mol) into the reaction bottle at 25-30 ℃, heating to reflux, stirring, cooling, crystallizing and filtering, leaching a filter cake with methanol, drying by blowing at 40-50 ℃ to obtain 41.1g of Vonopalagen fumarate, wherein the yield is about 89%.
Example 4
(1) Preparation of Compound II
Figure BDA0003350475870000121
Tetrahydrofuran is added into a reaction bottle, stirring is started, oxalyl chloride (7.6g, 0.06mol) is added, stirring is carried out until the mixture is dissolved, triphenylphosphine (52.5g, 0.2mol) is added into the system at the temperature of 0-5 ℃ to form white suspension, compound I (15.9g, 0.1mol) is added into the reaction bottle, barium azide (22.1g, 0.1mol) is added into the system, the temperature is raised to room temperature after the addition, the mixture is stirred at the room temperature until the reaction is finished, the mixture is concentrated under reduced pressure until no fraction is formed, ethyl acetate and cold purified water are added into the residue to wash the mixture, the mixture is separated, the organic phase is dried by anhydrous sodium sulfate, and 17.3g of compound II is obtained after the concentration, and the yield is 94%.
MS:m/z:185.0[M+1]
(2) Preparation of Compound IV
Figure BDA0003350475870000122
Acetonitrile is added into a reaction bottle at room temperature, stirring is started, a compound II (18.4g, 0.1mol), a compound III (18.6g, 0.11mol), catechol (0.55g, 0.005mol) and cuprous acetate (1.23g, 0.01mol) are added, stirring is carried out at room temperature until the reaction is finished, the reaction liquid is decompressed and concentrated to no fraction, and drying is carried out, so that 32.8g of a compound IV is obtained, and the yield is about 93%.
MS:m/z:354.1[M+1]
1H NMR(400MHz,CDCl3):1.42(s,9H),3.21(s,3H),4.22(d,2H),7.69(t,1H),8.32(s,1H), 8.43(d,1H),8.89-8.91(d,2H)
(3) Preparation of Compound VII
Figure BDA0003350475870000131
Adding 1.2-dichloroethane into a reaction bottle at room temperature, starting stirring, adding a compound IV (35.3g, 0.1mol), dimeric rhodium acetate (0.44g, 0.001mol) and a compound VI (63.1g,0.3mol), heating to 80 ℃ after the addition, stirring to react until the reaction is finished, cooling to room temperature, dissolving trimethylsilyl trifluoromethanesulfonate (TMSOTf) (1.1g, 0.005mol) in 1.2-dichloroethane, adding the system, stirring at room temperature, adding purified water and dichloromethane into the system for extraction, washing a water phase twice by using dichloro, combining organic phases, washing once by using water, and concentrating under reduced pressure to obtain 37.4g of a compound VII with the yield of about 84%.
MS:m/z:446.1[M+1]
(4) Preparation of Vonola fumarate
Figure BDA0003350475870000132
Adding a compound VII (44.6g, 0.1mol) into a reaction bottle at room temperature, adding trifluoroacetic acid (100ml), controlling the temperature to be 0-5 ℃ and stirring, adding a 20% sodium carbonate solution to adjust the pH value to be 9-10, collecting an organic phase, adding dichloromethane into a water phase to extract once, combining the organic phase, washing twice, drying the organic phase with anhydrous sodium sulfate, concentrating under reduced pressure to obtain Vonopalagen free alkali, adding methanol into the Vonopalagen free alkali to stir and dissolve, adding fumaric acid (11.6g, 0.1mol) into the reaction bottle at 25-30 ℃, heating to reflux, stirring, cooling, crystallizing and filtering, leaching a filter cake with methanol, drying by blowing at 40-50 ℃ to obtain 41.1g of Vonopalagen fumarate, wherein the yield is about 89%.
Example 5
(1) Preparation of Compound II
Figure BDA0003350475870000133
Tetrahydrofuran is added into a reaction bottle, stirring is started, oxalyl chloride (7.6g, 0.06mol) is added, stirring is carried out until the mixture is dissolved, triphenylphosphine (52.5g, 0.2mol) is added into the system at the temperature of 0-5 ℃ to form a white suspension, a compound I (15.9g, 0.1mol) is added into the reaction bottle, lithium azide (4.9g, 0.1mol) is added into the system, the temperature is increased to the room temperature after the addition, the stirring is carried out at the room temperature until the reaction is finished, the mixture is concentrated under reduced pressure until no fraction is formed, ethyl acetate and cold purified water are added into the residue to wash the mixture, the mixture is separated, the organic phase is dried by anhydrous sodium sulfate, and the compound II is obtained after the concentration, wherein the compound II is 17.1g, and the yield is 93%.
MS:m/z:185.0[M+1]
(2) Preparation of Compound IV
Figure BDA0003350475870000141
Acetonitrile is added into a reaction bottle at room temperature, stirring is started, a compound II (18.4g, 0.1mol), a compound III (18.6g, 0.11mol), hydroquinone (0.55g, 0.005mol) and cuprous acetate (1.23g, 0.01mol) are added, stirring is carried out at room temperature until the reaction is finished, the reaction liquid is decompressed and concentrated to no fraction, and drying is carried out, so that 32.8g of a compound IV is obtained, and the yield is about 93%.
MS:m/z:354.1[M+1]
1H NMR(400MHz,CDCl3):1.42(s,9H),3.21(s,3H),4.22(d,2H),7.69(t,1H),8.32(s,1H), 8.43(d,1H),8.89-8.91(d,2H)
(3) Preparation of Compound VII
Figure BDA0003350475870000142
Adding 1.2-dichloroethane into a reaction bottle at room temperature, starting stirring, adding a compound IV (35.3g, 0.1mol), dimeric rhodium acetate (0.44g, 0.001mol) and a compound VI (63.1g,0.3mol), heating to 80 ℃ after the addition, stirring to react until the reaction is finished, cooling to room temperature, dissolving trimethylsilyl trifluoromethanesulfonate (TMSOTf) (1.1g, 0.005mol) in 1.2-dichloroethane, adding the system, stirring at room temperature, adding purified water and dichloromethane into the system for extraction, washing a water phase twice by using dichloro, combining organic phases, washing once by using water, and concentrating under reduced pressure to obtain 37.4g of a compound VII with the yield of about 84%.
MS:m/z:446.1[M+1]
(4) Preparation of Vonola fumarate
Figure BDA0003350475870000151
Adding a compound VII (44.6g, 0.1mol) into a reaction bottle at room temperature, adding trifluoroacetic acid (100ml), controlling the temperature to be 0-5 ℃ and stirring, adding a 20% sodium carbonate solution to adjust the pH value to be 9-10, collecting an organic phase, adding dichloromethane into a water phase to extract once, combining the organic phase, washing twice, drying the organic phase with anhydrous sodium sulfate, concentrating under reduced pressure to obtain Vonopalagen free alkali, adding methanol into the Vonopalagen free alkali to stir and dissolve, adding fumaric acid (11.6g, 0.1mol) into the reaction bottle at 25-30 ℃, heating to reflux, stirring, cooling, crystallizing and filtering, leaching a filter cake with methanol, drying by blowing at 40-50 ℃ to obtain 41.1g of Vonopalagen fumarate, wherein the yield is about 89%.
Example 6
Process for preparing compounds of formula VI
Figure BDA0003350475870000152
Adding acetonitrile into a reaction bottle, starting stirring, adding a compound V (13.8g, 0.1mol) and sodium iodide (18.0g, 0.12mol), replacing nitrogen for three times, stirring at room temperature, adding triethylamine and trimethylchlorosilane (13.0g, 0.12mol) into the system, stirring at room temperature, cooling to below 0 ℃, controlling the temperature to be not more than 0 ℃, adding a saturated ammonium chloride solution and petroleum ether into the system, separating liquid, washing a water phase twice with the petroleum ether, combining organic phases, washing with ice water and saturated ammonium chloride, drying with anhydrous sodium sulfate, concentrating under reduced pressure until no fraction is formed, distilling and purifying residues under reduced pressure to obtain a compound VI 20.4g, wherein the yield is 97%.
Example 7
Process for preparing compounds of formula VI
Figure BDA0003350475870000153
Adding acetonitrile into a reaction bottle, starting stirring, adding a compound V (13.8g, 0.1mol), replacing nitrogen for three times, stirring at room temperature, adding triethylamine and hexamethyldisilazane (19.3g, 0.12mol) into the system, stirring at room temperature, cooling to below 0 ℃, controlling the temperature to be not more than 0 ℃, adding a saturated ammonium chloride solution and petroleum ether into the system, separating, washing a water phase twice with petroleum ether, combining organic phases, washing with ice water and saturated ammonium chloride, drying with anhydrous sodium sulfate, concentrating under reduced pressure until no fraction is formed, distilling and purifying residues under reduced pressure to obtain 19.4g of a compound VI with the yield of 92%.
Example 8
Process for preparing compounds of formula VI
Figure BDA0003350475870000161
Adding acetonitrile into a reaction bottle, starting stirring, adding a compound V (13.8g, 0.1mol), replacing nitrogen for three times, stirring at room temperature, adding triethylamine and trimethylsilyldiethylamine (17.4g, 0.12mol) into the system, stirring at room temperature, cooling to below 0 ℃, controlling the temperature to be not more than 0 ℃, adding a saturated ammonium chloride solution and petroleum ether into the system, separating liquid, washing a water phase twice with petroleum ether, combining organic phases, washing with ice water and saturated ammonium chloride, drying with anhydrous sodium sulfate, concentrating under reduced pressure until no fraction is produced, distilling and purifying residues under reduced pressure to obtain 19.4g of a compound VI with the yield of 92%.

Claims (20)

1. A process for preparing a compound of formula vii, comprising the steps of:
Figure FDA0003350475860000011
carrying out condensation reaction on a compound shown as a formula IV and a compound shown as a formula VI to obtain a compound shown as a formula VII
Figure FDA0003350475860000012
2. The process for producing a compound represented by the formula VII according to claim 1, wherein the condensation reaction catalyst comprises an organorhodium reagent and an acid catalyst.
3. A process for the preparation of a compound of formula vii as claimed in claim 2 wherein the organorhodium reagent is dimeric rhodium acetate.
4. A compound of formula IV:
Figure FDA0003350475860000013
5. a process for preparing a compound of formula iv according to claim 4, comprising the steps of: carrying out cyclization reaction on a compound shown as a formula II and a compound shown as a formula III to obtain a compound shown as a formula IV
Figure FDA0003350475860000021
6. The process for preparing a compound of formula iv according to claim 5, wherein the cyclization catalyst is a copper catalyst and a ligand.
7. The method of claim 6, wherein the copper catalyst is cuprous acetate, cupric sulfate, or cuprous iodide.
8. The method of claim 6, wherein the ligand is selected from the group consisting of aminophenols, phenylenediamines, benzenediols, and anilines.
9. A process for preparing a compound of formula ii, said process comprising the steps of:
Figure FDA0003350475860000022
carrying out azide reaction on the formula I to obtain a compound shown as a formula II
Figure FDA0003350475860000023
10. The method for preparing the compound represented by the formula ii according to claim 9, wherein the azide reaction is performed using an azide reagent selected from the group consisting of sodium azide, potassium azide, lithium azide, magnesium azide, cesium azide and barium azide.
11. A preparation method of Voranolan fumarate is characterized by comprising the following steps:
deprotecting a compound of formula VII prepared according to the process of claim 1 with an acid to obtain Voranol free base; and salifying the Voranol free alkali and fumaric acid to obtain Voranol fumarate.
12. A preparation method of Voranolan fumarate is characterized by comprising the following steps:
(1) carrying out azide reaction on the compound shown as the formula I to obtain the compound shown as the formula II
Figure FDA0003350475860000031
(2) Cyclizing the compound shown as the formula II and the compound shown as the formula III to obtain the compound shown as the formula IV
Figure FDA0003350475860000032
(3) Carrying out condensation reaction on a compound shown as a formula IV and a compound shown as a formula VI to obtain a compound shown as a formula VII
Figure FDA0003350475860000033
(4) Deprotecting the compound shown in the formula VII by using acid to obtain Voronalane free base;
(5) the Voranolan free alkali and fumaric acid form salt to obtain Voranolan fumarate.
13. The process for preparing Vonola fumarate of claim 12, wherein in the azidation reaction of step (1), the azidation reagent used is one selected from the group consisting of sodium azide, potassium azide, lithium azide, magnesium azide, cesium azide and barium azide.
14. The process for the preparation of vorexant fumarate according to claim 12, wherein the cyclization catalyst in step (2) is a copper catalyst and a ligand.
15. The process for the preparation of vorexan fumarate according to claim 14, wherein the copper catalyst is cuprous acetate, cupric sulfate or cuprous iodide.
16. The process for the preparation of vorexant fumarate of claim 14, wherein the ligand is selected from one of aminophenol, phenylenediamine, benzenediol and aniline.
17. The process for the preparation of vorexant fumarate according to claim 12, wherein the condensation reaction catalyst in step (3) is an organorhodium reagent and an acid catalyst.
18. The process for the preparation of vorexant fumarate of claim 17, wherein the organorhodium reagent is dimeric rhodium acetate.
19. A process for preparing a compound of formula VI, comprising the steps of,
Figure FDA0003350475860000041
carrying out condensation reaction on the compound shown as the formula V and a trimethyl silanization reagent to obtain the compound shown as the formula VI
Figure FDA0003350475860000042
20. The method of claim 19, wherein the trimethylsilylating agent is selected from the group consisting of iodotrimethylsilane, bromotrimethylsilane, hexamethyldisilazane, and trimethylsilyldiethylamine.
CN202111335839.7A 2021-11-12 2021-11-12 Preparation method of Voranolan fumarate Pending CN113861167A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111335839.7A CN113861167A (en) 2021-11-12 2021-11-12 Preparation method of Voranolan fumarate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111335839.7A CN113861167A (en) 2021-11-12 2021-11-12 Preparation method of Voranolan fumarate

Publications (1)

Publication Number Publication Date
CN113861167A true CN113861167A (en) 2021-12-31

Family

ID=78984370

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111335839.7A Pending CN113861167A (en) 2021-11-12 2021-11-12 Preparation method of Voranolan fumarate

Country Status (1)

Country Link
CN (1) CN113861167A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114539219A (en) * 2022-03-17 2022-05-27 日照正济药业有限公司 Preparation method of Voranolan fumarate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085484A (en) * 2015-08-21 2015-11-25 南京济群医药科技有限公司 Preparation method of vonoprazan fumarate
CN106366071A (en) * 2016-08-22 2017-02-01 山东金城医药股份有限公司 Vonoprazan fumarate preparation method
CN107915720A (en) * 2016-10-08 2018-04-17 常州市第四制药厂有限公司 The new preparation process of Wo Nuolazan
CN108503621A (en) * 2017-12-25 2018-09-07 上海中拓医药科技有限公司 A kind of preparation method of Vonoprazan fumarate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085484A (en) * 2015-08-21 2015-11-25 南京济群医药科技有限公司 Preparation method of vonoprazan fumarate
CN106366071A (en) * 2016-08-22 2017-02-01 山东金城医药股份有限公司 Vonoprazan fumarate preparation method
CN107915720A (en) * 2016-10-08 2018-04-17 常州市第四制药厂有限公司 The new preparation process of Wo Nuolazan
CN108503621A (en) * 2017-12-25 2018-09-07 上海中拓医药科技有限公司 A kind of preparation method of Vonoprazan fumarate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADELEH KIANI等: ""Direct synthesis of sulfonyl azides from sulfonic acids"", 《JOURNAL OF SULFUR CHEMISTRY》, vol. 35, no. 2, pages 119 - 127 *
JUAN FENG ET AL.: ""Facile synthesis of pyrroles via Rh(II)-catalyzed transannulation of 1-tosyl-1, 2, 3-triazoles with silyl or alkyl enol ethers"", 《TETRAHEDRON LETTERS》, vol. 55, no. 47, pages 6455 - 6458, XP029089262, DOI: 10.1016/j.tetlet.2014.09.134 *
QIYU LUO等: ""Photoredox-Catalyzed Generation of Sulfamyl Radicals:Sulfonamidation of Enol Silyl Ether with Chlorosulfonamide"", 《J. ORG. CHEM》, vol. 84, pages 13897 *
YANTAO LIU等: ""Highly controlling selectivity of copper(I)-catalyzed azide/alkyne cycloaddition (CuAAC) between sulfonyl azids and normal alkynes or propynoates"", 《TETRAHEDRON》, vol. 67, no. 34, pages 6294 - 6299, XP028381876, DOI: 10.1016/j.tet.2011.06.017 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114539219A (en) * 2022-03-17 2022-05-27 日照正济药业有限公司 Preparation method of Voranolan fumarate

Similar Documents

Publication Publication Date Title
CN111423452B (en) Intermediate of Rayleigh Lu Geli and preparation method and application thereof
US8440831B2 (en) Process and intermediates for preparing integrase inhibitors
EP2069280B1 (en) Process and intermediates for preparing HIV integrase inhibitors
JP5161023B2 (en) Process for producing piperazine derivatives
CN106866553A (en) A kind of synthetic method of Favipiravir
CN107857743B (en) Method for preparing roxatidine acetate hydrochloride and intermediate
US20180044358A1 (en) Method for producing dialkylaminosilane
CN110950765A (en) Preparation method of terbutaline sulfate
CN114805314A (en) Synthesis method of Ensaitevir
CN106660959B (en) The preparation method of 3- hydroxy-picolinic acid
CN113861167A (en) Preparation method of Voranolan fumarate
US20050059692A1 (en) Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one
JP7227925B2 (en) Method for producing 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate
CN111646936A (en) Process for producing aromatic ether compound
CN112272665A (en) Process for preparing sitagliptin
CN111100112B (en) Benzothiophene derivative and process for producing the same
CN111217709A (en) Preparation method of (1-fluorocyclopropyl) methylamine hydrochloride
CN107556237B (en) Preparation method of 3- (2-phenethyl) -2-pyridine carboxamide compound
CN111187197B (en) Synthesis method of Tezacaftor intermediate
JP4181233B2 (en) Method for producing pyrrolidine-2,4-dione derivative
JP2022035954A (en) N-boc-lactam derivative and method for producing the same, and method for producing cyclic amine derivative
EP1698611A1 (en) Process for producing phenylacetic acid derivative
CN115819303A (en) Preparation method of compound 3-fluoro-4-isothiocyanato-2-trifluoromethyl benzonitrile
CN117534613A (en) Preparation method of 3-aminopyridine-2-carboxylic acid methyl ester
CN114560862A (en) Synthesis method of pyrrolo [1,2-A ] quinoxaline-4 (5H) -ketone and derivative thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination